Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Trauner

Showing results (671-680 of 777) with videos related to

Pageof 78
Sort By:
Journal of the American College of Cardiology|February 4, 2012
Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trialStephan von Haehling, Joerg C Schefold, Ewa A Jankowska, et al.
The American Journal of Clinical Nutrition|December 5, 2019
Metabolic effects of a prolonged, very-high-dose dietary fructose challenge in healthy subjectsSabina Smajis, Martin Gajdošík, Lorenz Pfleger, et al.
The Lancet. Gastroenterology & Hepatology|July 27, 2019
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trialStefan Traussnigg, Jörn M Schattenberg, Münevver Demir, et al.
Iscience|March 12, 2024
Transcriptomic signatures of progressive and regressive liver fibrosis and portal hypertensionOleksandr Petrenko, Philipp Königshofer, Ksenia Brusilovskaya, et al.
Hepatology (Baltimore, Md.)|October 30, 2021
Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologiesPhilipp Königshofer, Benedikt Silvester Hofer, Ksenia Brusilovskaya, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 16, 2021
Epidemiological trends of HBV and HDV coinfection among Viennese HIV+ patientsCaroline Schmidbauer, David Chromy, Victor U Schmidbauer, et al.
JHEP Reports : Innovation in Hepatology|February 12, 2026
Treatment response to bulevirtide is linked to amelioration of portal hypertension in patients with chronic hepatitis DLisa Sandmann, Mathias Jachs, Tammo L Tergast, et al.
Scientific Reports|July 30, 2024
Rapid improvement of hepatic steatosis and liver stiffness after metabolic/bariatric surgery: a prospective studyLarissa Nixdorf, Lukas Hartl, Stefanie Ströhl, et al.
Journal of Hepatology|June 24, 2022
Soluble TREM2 levels reflect the recruitment and expansion of TREM2<sup>+</sup> macrophages that localize to fibrotic areas and limit NASHTim Hendrikx, Florentina Porsch, Máté G Kiss, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 13, 2022
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver diseaseBenedikt Simbrunner, Ida Falk Villesen, Philipp Königshofer, et al.
Pageof 78

Showing results (671-680 of 777) with videos related to

Sort By:
Pageof 78
Journal of the American College of Cardiology|February 4, 2012
Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trialStephan von Haehling, Joerg C Schefold, Ewa A Jankowska, et al.
The American Journal of Clinical Nutrition|December 5, 2019
Metabolic effects of a prolonged, very-high-dose dietary fructose challenge in healthy subjectsSabina Smajis, Martin Gajdošík, Lorenz Pfleger, et al.
The Lancet. Gastroenterology & Hepatology|July 27, 2019
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trialStefan Traussnigg, Jörn M Schattenberg, Münevver Demir, et al.
Iscience|March 12, 2024
Transcriptomic signatures of progressive and regressive liver fibrosis and portal hypertensionOleksandr Petrenko, Philipp Königshofer, Ksenia Brusilovskaya, et al.
Hepatology (Baltimore, Md.)|October 30, 2021
Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologiesPhilipp Königshofer, Benedikt Silvester Hofer, Ksenia Brusilovskaya, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 16, 2021
Epidemiological trends of HBV and HDV coinfection among Viennese HIV+ patientsCaroline Schmidbauer, David Chromy, Victor U Schmidbauer, et al.
JHEP Reports : Innovation in Hepatology|February 12, 2026
Treatment response to bulevirtide is linked to amelioration of portal hypertension in patients with chronic hepatitis DLisa Sandmann, Mathias Jachs, Tammo L Tergast, et al.
Scientific Reports|July 30, 2024
Rapid improvement of hepatic steatosis and liver stiffness after metabolic/bariatric surgery: a prospective studyLarissa Nixdorf, Lukas Hartl, Stefanie Ströhl, et al.
Journal of Hepatology|June 24, 2022
Soluble TREM2 levels reflect the recruitment and expansion of TREM2<sup>+</sup> macrophages that localize to fibrotic areas and limit NASHTim Hendrikx, Florentina Porsch, Máté G Kiss, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 13, 2022
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver diseaseBenedikt Simbrunner, Ida Falk Villesen, Philipp Königshofer, et al.
Pageof 78